Canagliflozin and cardiovascular outcomes in Type 2 diabetes.
SGLT2
Type 2 diabetes
canagliflozin
cardiovascular disease
chronic kidney disease
nephropathy
sodium glucose cotransporter 2 inhibitors
Journal
Future cardiology
ISSN: 1744-8298
Titre abrégé: Future Cardiol
Pays: England
ID NLM: 101239345
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
5
8
2020
medline:
26
10
2021
entrez:
5
8
2020
Statut:
ppublish
Résumé
SGLT2 inhibitors have risen to prominence in recent years as Type 2 diabetes mellitus medications with favorable effects on cardiovascular (CV) and renal outcomes. Canagliflozin is a US FDA-approved SGLT2 inhibitor that has demonstrated CV and renal outcome benefits in large scale placebo-controlled randomized trials of patients with Type 2 diabetes mellitus and elevated CV risk. Canagliflozin use may also be associated with serious and nonserious adverse effects requiring ongoing monitoring in patients initiated on this medication. This paper provides a detailed overview of canagliflozin including its pharmacologic profile, clinical efficacy and safety data, with discussion of both clinical trial results, as well as real-world evidence.
Identifiants
pubmed: 32748638
doi: 10.2217/fca-2020-0029
pmc: PMC8656317
doi:
Substances chimiques
Hypoglycemic Agents
0
Sodium-Glucose Transporter 2 Inhibitors
0
Canagliflozin
0SAC974Z85
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
39-48Subventions
Organisme : NHLBI NIH HHS
ID : K01 HL144607
Pays : United States
Références
Curr Vasc Pharmacol. 2021;19(2):233-240
pubmed: 32183678
Circulation. 2017 Jul 18;136(3):249-259
pubmed: 28522450
Lancet Diabetes Endocrinol. 2020 Jan;8(1):27-35
pubmed: 31862149
Glob Heart. 2013 Mar 1;8(1):43-48
pubmed: 23544179
Circulation. 2020 Feb 4;141(5):407-410
pubmed: 31707795
Diabetes Obes Metab. 2014 May;16(5):467-77
pubmed: 24528605
Metabolism. 2014 Oct;63(10):1228-37
pubmed: 25104103
Nutr Metab Cardiovasc Dis. 2017 Dec;27(12):1108-1113
pubmed: 29174031
J Am Coll Cardiol. 2019 Sep 10;74(10):e177-e232
pubmed: 30894318
Cardiovasc Diabetol. 2019 May 28;18(1):64
pubmed: 31138195
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Hypertension. 2020 Apr;75(4):894-901
pubmed: 32114848
Redox Biol. 2020 May;32:101527
pubmed: 32278282
Diabetes Obes Metab. 2018 Jun;20(6):1531-1534
pubmed: 29430814
Int J Clin Pract. 2013 Dec;67(12):1267-82
pubmed: 24118688
J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639
pubmed: 29540325
Endocrinol Diabetes Metab. 2019 Oct 15;3(1):e00096
pubmed: 31922023
Kidney Int. 2014 Oct;86(4):693-700
pubmed: 24257692
Diabetes Obes Metab. 2009 Feb;11(2):150-6
pubmed: 18671796
Expert Rev Clin Pharmacol. 2014 Jan;7(1):21-3
pubmed: 24308786
Nat Rev Nephrol. 2017 Jan;13(1):11-26
pubmed: 27941935
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Diabetologia. 2019 Jun;62(6):926-938
pubmed: 30868176
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Diabetes Obes Metab. 2018 Nov;20(11):2585-2597
pubmed: 29938883
N Engl J Med. 2008 Jun 12;358(24):2545-59
pubmed: 18539917
Lancet. 1998 Sep 12;352(9131):854-65
pubmed: 9742977
Clin Pharmacokinet. 2015 Oct;54(10):1027-41
pubmed: 26041408
Lancet. 2013 Sep 14;382(9896):941-50
pubmed: 23850055
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
Postgrad Med. 2016 May;128(4):371-80
pubmed: 27002421
Diabetes Metab Syndr Obes. 2019 Feb 01;12:209-215
pubmed: 30787627
Curr Med Res Opin. 2016 Aug;32(8):1375-85
pubmed: 27046479
Circulation. 2012 Dec 18;126(25):e354-471
pubmed: 23166211
Curr Med Res Opin. 2014 Feb;30(2):163-75
pubmed: 24073995
Circulation. 2017 Mar 7;135(10):e146-e603
pubmed: 28122885
N Engl J Med. 2008 Jun 12;358(24):2560-72
pubmed: 18539916
Diabetes Care. 2015 Dec;38(12):2344-53
pubmed: 26604280
Diabetes Obes Metab. 2018 Mar;20(3):582-589
pubmed: 28898514